Skip to main content
. 2024 May 5;12(5):500. doi: 10.3390/vaccines12050500

Figure A18.

Figure A18

Vaccine efficacy (VE) for respiratory syncytial virus (RSV) vaccines in older adults (age ≥ 60 years) with lower respiratory tract disease (LRTD) with 3 signs/symptoms or more in follow-up studies (I2 0.0%, 95% CI 0.0 to 89.6; tau2 0.003, 95% CI 0.0 to 5.411; Q = 1.19, p = 0.553) [48,61,85].